alpha-aminopyridine has been researched along with Small Cell Lung Carcinoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Rahman, O; de Sousa, MJ; Fazio, N; Gervaso, L; Meneses-Medina, MI; Spada, F | 1 |
| Chen, L; Cress, WD; Kurtyka, CA | 1 |
| Byers, LA; Cardnell, RJ; Diao, L; Fan, Y; Feng, Y; Heymach, JV; Masrorpour, F; Mukherjee, S; Nilsson, M; Shen, Y; Stewart, CA; Tong, P; Wang, J | 1 |
| Ali, SM; Fernandez-Rocha, MY; Gitlitz, BJ; Lee, TK; Milliken, J; Ou, SI; Pavlick, D; Schrock, AB; Young, L; Zhu, VW | 1 |
| Chang, RP; Giaccone, G; Harada, T; Killian, JK; Lucchi, M; Meltzer, PS; Smith, WI; Suuriniemi, M; Voortman, J; Wang, Y | 1 |
1 review(s) available for alpha-aminopyridine and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside.
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Lung Neoplasms; Neuroendocrine Tumors; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
4 other study(ies) available for alpha-aminopyridine and Small Cell Lung Carcinoma
| Article | Year |
|---|---|
E2F inhibition synergizes with paclitaxel in lung cancer cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; E2F3 Transcription Factor; Gemcitabine; Humans; Hydroxyquinolines; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; RNA, Small Interfering; Small Cell Lung Carcinoma | 2014 |
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Topics: Aminopyridines; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Female; Humans; Indoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Signal Transduction; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Crizotinib; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Retinoblastoma Binding Proteins; Small Cell Lung Carcinoma; Ubiquitin-Protein Ligases | 2017 |
Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Humans; Indoles; Lung Neoplasms; Mutation; Neuroendocrine Tumors; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-met; Pyridones; Small Cell Lung Carcinoma; Sulfonamides | 2013 |